- freely available
Oromucosal Administration of Interferon to Humans
AbstractThe prevailing dogma is that, to be systemically effective, interferon-alpha (IFNα) must be administered in sufficiently high doses to yield functional blood concentrations. Such an approach to IFNa therapy has proven effective in some instances, but high-dose parenteral IFNα therapy has the disadvantage of causing significant adverse events. Mounting evidence suggests that IFNα delivered into the oral cavity in low doses interacts with the oral mucosa in a unique manner to induce systemic host defense mechanisms without IFNα actually entering the circulation, thus reducing the potential for toxic side effects. A better understanding of the applications and potential benefits of this treatment modality are under active investigation. This paper provides a review of the relevant literature on the clinical use of the oromucosal route of administration of interferon, with an emphasis on the treatment of influenza.
Share & Cite This Article
Beilharz, M.W.; Cummins, M.J.; Bennett, A.L.; Cummins, J.M. Oromucosal Administration of Interferon to Humans. Pharmaceuticals 2010, 3, 323-344.View more citation formats
Beilharz MW, Cummins MJ, Bennett AL, Cummins JM. Oromucosal Administration of Interferon to Humans. Pharmaceuticals. 2010; 3(2):323-344.Chicago/Turabian Style
Beilharz, Manfred W.; Cummins, Martin J.; Bennett, Alayne L.; Cummins, Joseph M. 2010. "Oromucosal Administration of Interferon to Humans." Pharmaceuticals 3, no. 2: 323-344.
Notes: Multiple requests from the same IP address are counted as one view.